TLDR
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock jumped 154% in premarket trading after announcing a telehealth partnership with Runway Health
- The partnership launches April 2, 2026, integrating ARAKODA malaria prevention drug into Runway Health’s online platform for travelers
- ARAKODA is the only FDA-approved once-weekly malaria prevention medication available in the U.S. market
- The telehealth service will offer physician consultations online with home delivery of prescriptions before travel to malaria-endemic areas
- Despite 128.7% revenue growth in the last twelve months, the company trades at $2.00 per share, down 88% over the past year
60 Degrees Pharmaceuticals saw its stock price explode Thursday morning. The company’s shares jumped 154% in premarket trading after announcing a new distribution deal for its malaria prevention drug.
60 Degrees Pharmaceuticals, Inc., SXTP
The pharmaceutical company partnered with Runway Health to expand access to ARAKODA. The drug prevents malaria in travelers heading to high-risk regions.
The partnership goes live April 2, 2026. It will put ARAKODA on Runway Health’s direct-to-patient telehealth platform.
The setup makes getting the drug simpler. Travelers can consult with physicians online before their trips. If prescribed, the medication arrives at their door before departure.
ARAKODA holds a unique position in the market. It’s the only FDA-approved, broad-spectrum, once-weekly malaria prevention medication sold in the United States.
How the Telehealth Platform Works
The Runway Health platform matches travel plans with medical treatment options. U.S. licensed healthcare providers design personalized plans based on each traveler’s itinerary.
The dosing schedule differs from daily alternatives. Patients take two 100 mg tablets daily for three days before travel. During travel, they take two tablets weekly for up to six months. A final two-tablet dose comes in the week after returning home.
Walter Reed Army Institute of Research discovered the drug. The FDA approved it for malaria prevention in 2018.
Market Performance and Revenue Growth
The stock currently trades at $2.00 per share. Over the past year, shares dropped 88%. The 52-week range spans from $1.36 to $24.00.
Revenue tells a different story. The company posted 128.7% revenue growth in the last twelve months. However, losses continue with an EBITDA of negative $7.63 million.
The company announced a one-for-four reverse stock split earlier this month. The split took effect January 20, 2026, designed to meet Nasdaq’s minimum bid price requirement.
Malaria transmission occurs through Anopheles mosquito bites. The disease ranks among the world’s most serious infectious threats. Without treatment, it can become fatal.
Not all patients can use ARAKODA. The drug isn’t suitable for people with G6PD deficiency, pregnant or breastfeeding women with G6PD-deficient infants, patients with psychotic disorders, or those with hypersensitivity to tafenoquine.
H.C. Wainwright recently started coverage on 60 Degrees Pharmaceuticals. The firm issued a Buy rating with a $6.00 price target.
The company is also running clinical trials for other uses of tafenoquine. Patient enrollment began for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine. A North Carolina State University study found Babesia parasite infection in 24% of chronic fatigue patients.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
